| 1 |
Jamee M, Moniri S, Zaki-Dizaji M, et al.Clinical, immunological, and genetic features in patients with activated PI3Kδ syndrome (APDS):a systematic review [J].Clin Rev Allergy Immunol, 2020, 59(3): 323-333.
|
| 2 |
Angulo I, Vadas O, Garçon F, et al.Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage [J].Science, 2013, 342(6160): 866-871.
|
| 3 |
刘辉, 唐晓蕾, 刘金荣, 等.PIK3CD 基因突变所致激活PI3K-δ 综合征的临床特点和基因分析 [J].中华儿科杂志, 2016, 54(9): 698-702.
|
| 4 |
Lucas CL, Chandra A, Nejentsev S, et al.PI3Kδ and primary immunodeficiencies [J].Nat Rev Immunol, 2016, 16(11): 702-714.
|
| 5 |
Coulter TI, Chandra A, Bacon CM, et al.Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study [J].J Allergy Clin Immunol, 2017, 139(2): 597-606.e4.
|
| 6 |
Vanselow S, Wahn V, Schuetz C.Activated PI3Kδ syndrome -reviewing challenges in diagnosis and treatment [J].Front Immunol,2023, 14: 1208567.
|
| 7 |
Wentink M, Dalm V, Lankester AC, et al.Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections [J].Clin Immunol,2017, 176: 77-86.
|
| 8 |
Elkaim E, Neven B, Bruneau J, et al.Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: a cohort study [J].J Allergy Clin Immunol, 2016, 138(1):210-218.e9.
|
| 9 |
Brodsky NN, Lucas CL.Infections in activated PI3K delta syndrome(APDS) [J].Curr Opin Immunol, 2021, 72: 146-157.
|
| 10 |
Moriya K, Mitsui-Sekinaka K, Sekinaka Y, et al.Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan [J].Immunol Med, 2023, 46(4): 153-157.
|
| 11 |
高君伟, 刘皋林.自身免疫性疾病的药物治疗 [J/OL].中华临床医师杂志(电子版), 2023, 17(12): 1209-1211.
|
| 12 |
Maccari ME, Abolhassani H, Aghamohammadi A, et al.Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the European society for immunodeficienciesactivated phosphoinositide 3-kinase δ syndrome registry [J].Front Immunol, 2018, 9: 543.
|
| 13 |
Rao VK, Webster S, Šedivá A, et al.A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome [J].Blood, 2023, 141(9): 971-983.
|
| 14 |
Nademi Z, Slatter MA, Dvorak CC, et al.Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome [J].J Allergy Clin Immunol, 2017, 139(3): 1046-1049.
|
| 15 |
中华医学会儿科学分会免疫学组, 中华儿科杂志编辑委员会.原发性免疫缺陷病免疫球蛋白G 替代治疗专家共识 [J].中华儿科杂志, 2019, 57(12): 909-912.
|
| 16 |
杨夏影, 马银娟, 潘耀柱.PI3Kδ 过度活化综合征诊疗进展 [J].中国现代医学杂志, 2021, 31(6): 71-78.
|
| 17 |
Dimitrova D, Nademi Z, Maccari M E, et al.International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome[J].Journal of Allergy and Clinical Immunology,2022, 149(1): 410-421.e7.
|
| 18 |
中华医学会儿科学分会免疫学组.原发性免疫缺陷病的早期识别线索 [J].中华儿科杂志, 2015, 53(12): 893-897.
|